Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7 K/gp19 K region

Gene Therapy

Volumn 8, Issue 15, 2001, Pages 1123-1131

  Hermiston, T W ^a,b   Johnson, L ^a   Bauzon, M ^a   Nye, J A ^a   Castro, D ^a   Kitzes, G A ^a   Young, M D ^a   Holt, J K ^a   Trown, P ^a   Hawkins, L K ^a,c  

^a ONYX PHARMACEUTICALS   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c BAYER AG   (Germany)

Author keywords

Adenovirus; Armed therapeutic virus; E3 region; Gene delivery; Oncolytic; Replication selective

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; ONYX 015; ONYX 301; ONYX 302; ONYX 304; ONYX 323; ONYX 330; ONYX 340; PROTEIN P16; PROTEIN P53; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ADENOVIRUS; ARTICLE; CANCER CELL; CANCER THERAPY; CELL MUTANT; CONTROLLED STUDY; DNA REPLICATION; DRUG EFFICACY; ENHANCER REGION; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIFE CYCLE; METHODOLOGY; NUCLEOTIDE SEQUENCE; ONCOGENE H RAS; POLYADENYLATION; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; RNA SPLICING; TRANSGENE; VIRUS GENE; VIRUS REPLICATION;

ADENOVIRUS E3 PROTEINS; ADENOVIRUSES, HUMAN; BLOTTING, WESTERN; CELL LINE; CYTOSINE DEAMINASE; GENE EXPRESSION; GENE THERAPY; GENES, P16; GENETIC VECTORS; HUMANS; MUTAGENESIS, INSERTIONAL; NUCLEOSIDE DEAMINASES; TRANSFECTION; TRANSGENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17944371743     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301507     Document Type: Article

References (53)

1. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
2. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
3. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
4. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
5. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
6. Packaging capacity and stability of human adenovirus type 5 vectors
7. Generation of adenovirus by transfection of plasmids
8. Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian virus 40 genome
9. Adenovirus transcription. II. RNA sequences complementary to simian virus 40 and adenovirus 2 DNA in AD2+ND1- and AD2+ND3- infected cells
10. Adenovirus-based expression vectors and recombinant vaccines
11. Adenovirus vectors for gene expression
12. E3 transcription unit of adenovirus
13. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
14. Gene delivery from the E3 region of the replicating human adenovirus: Evaluation of the ADP region
15. Gene delivery from the E3 region of the replicating, human adenovirus: Evaluation of the E3B region
16. Evidence that AGUAUAUGA and CCAAGAUGA initiate translation in the same mRNA region E3 of adenovirus
17. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand
18. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
19. Escape from host-antitumor immunity
20. The immune system as antitumor sentinel: Molecular requirements for an anti-tumor immune response
21. Immunologic nonresponsiveness to tumors
22. Deletion mutants that alter differential RNA processing in the E3 complex transcription unit of adenovirus
23. The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells
24. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants
25. Complex splicing patterns of RNAs from the early regions of adenovirus-2
26. Genetic analysis of mRNA synthesis in adenovirus region E3 at different stages of productive infection by RNA-processing mutants
27. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors
28. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
29. Tumor necrosis factor enhances HLA-A, B, C and HLA-DR gene expression in human tumor cells
30. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats
31. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo
32. Limb desmoid tumors: A possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan
33. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation
34. Recombinant human tumor necrosis factor-alpha: Thrombus formation is a cause of anti-tumor activity
35. In vitro remodeling of tumor vascular endothelial cells using conditioned medium from various tumor cells and their sensitivity to TNF-alpha
36. An endotoxin-induced serum factor that causes necrosis of tumors
37. Molecular cloning of the complementary DNA for human tumor necrosis factor
38. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients
39. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease
40. Recombinant human tumor necrosis administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism
41. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study
42. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα
43. Preparation and titration of CsCl-banded adenovirus stock
44. Rapid insertional mutagenesis of DNA by polymerase chain reaction (PCR)
45. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
46. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP
47. Construction of mutations in the adenovirus early region 3 (E3) transcription units
48. Selective extraction of polyoma DNA from infected mouse cell cultures
49. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy
50. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy
51. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
52. A 14, 500 MW protein is coded by region E3 of group C human adenoviruses
53. Identification and gene mapping of a 14, 700-molecular-weight protein encoded by region E3 of group C adenoviruses